Form 4: AN2 Therapeutics Director's Stock Options Repriced

AN2 Therapeutics director Stephanie Wong's stock options for 59,103 shares were repriced to $3.91 per share on March 19, 2026.

Summary

• Stephanie Wong, a Director at AN2 Therapeutics, Inc. (ANTX), had 59,103 stock options repriced on March 19, 2026.
• The exercise price for these options was adjusted to $3.91 per share, which represented the closing price of the Issuer's common stock on the repricing date.
• The repricing affected three tranches of options with original exercise prices of $6.596, $17.28, and $5.91.
• All repriced options are fully vested.
• The repriced exercise price of $3.91 is conditional; it will revert to the original higher price if exercised or if Ms. Wong's services terminate prior to the 'Premium End Date' (earliest of September 19, 2027, a change in control, or Ms. Wong's death or disability).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal regarding past stock performance, as option repricing typically occurs when original options are significantly out-of-the-money. While it aims to re-incentivize the director, it can be perceived negatively by shareholders.

Positives

• The repricing of stock options to a lower exercise price of $3.91 per share could re-incentivize the director by making the options more 'in-the-money' or closer to the current market price, potentially aligning her interests with future shareholder value creation if the stock price rises above $3.91.

Negatives

• Repricing options typically indicates that the previous exercise prices were significantly 'out-of-the-money,' suggesting a substantial decline in the company's stock price since the original grant dates.
• The conditional nature of the repricing, where the price reverts to the original higher price under certain circumstances, adds complexity and potential uncertainty regarding the ultimate benefit to the director.
• Repricing options can be viewed negatively by shareholders as it effectively grants new value to executives/directors at a lower hurdle, potentially signaling poor past performance or diluting existing shareholder value.

Risks

• Shareholder Dilution/Sentiment: Repricing options, especially when the stock price has fallen, can be perceived negatively by shareholders, potentially impacting investor confidence.
• Conditional Repricing Risk: The 'Premium End Date' clause introduces a risk that the benefit of the lower exercise price could be lost if certain events (e.g., early exercise, termination of service, change in control) occur before September 19, 2027.
• Stock Price Volatility: The value of these options, even after repricing, remains subject to the future performance and volatility of AN2 Therapeutics' common stock.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the conditional nature of the repriced options and their expiration dates. The repricing itself implies a management effort to re-incentivize directors given past stock performance.

Management Comments

• The board of directors of the Issuer approved the repricing of the option.
• The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing.

Industry Context

StockSavvy.ai notes that option repricing is a common practice in industries, particularly biotechnology or early-stage companies, where stock prices can be highly volatile. It often occurs after a significant decline in share price to restore the incentive value of employee and director equity awards. While it can re-motivate key personnel, it can also be viewed critically by investors as a form of 're-setting the bar' after underperformance, potentially signaling challenges in achieving original growth targets.

Comparison to Industry Standards

• Repricing options is a practice seen across various industries, especially in sectors with high R&D costs and volatile stock performance like biotechnology. For example, companies like Biogen or Moderna have faced periods of stock price declines where similar compensation adjustments might be considered to retain talent.
• The conditional nature of the repricing, where the price reverts to the original if certain events occur before a 'Premium End Date,' is a less common but not unheard-of mechanism designed to mitigate some of the negative optics of a straight repricing, potentially linking the benefit more directly to future performance or continued service.
• Compared to broader market benchmarks like the S&P 500, where executive compensation often relies on performance-based vesting schedules tied to specific financial metrics, this repricing event is a direct adjustment to the strike price of existing options, reflecting a more immediate response to stock price movements rather than a long-term performance incentive structure.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative perception due to option repricing often signaling past stock underperformance; potential dilution if new options were granted, though here it's a repricing of existing ones. The conditional nature might mitigate some concerns.
• Director (Stephanie Wong): Increased incentive and potential value from her stock options, as the exercise price is now closer to or below the current market price, making them more likely to be 'in-the-money.'
• Employees: Could set a precedent or expectation for similar adjustments for other employees if their options are also underwater.

Next Steps

• Continued service of Stephanie Wong with AN2 Therapeutics.
• Potential exercise of the repriced options by Stephanie Wong, subject to the 'Premium End Date' conditions.

Key Dates

Recommendation

The repricing of director stock options indicates that the company's stock price has likely underperformed, making the original options out-of-the-money. While the repricing aims to re-incentivize the director, it doesn't fundamentally change the company's underlying business prospects or financial health as disclosed in this filing. Investors should hold and await further operational and financial updates to assess the company's future trajectory and the effectiveness of this incentive adjustment.

Keywords

AN2 Therapeutics, ANTX, Stock Options, Repricing, Form 4, Director Compensation, Equity Compensation, Corporate Governance, Beneficial Ownership